Management of colorectal cancer in older patients

ONCOLOGY

Volumn 20, Issue 7, 2006, Pages 741-750

  Xiao, Han ^a   Lichtman, Stuart M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGING; ALLERGY; ALOPECIA; ANAMNESIS; ARTERY THROMBOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; EVIDENCE BASED MEDICINE; GERIATRIC CARE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY FUNCTION TEST; LABORATORY TEST; LEUKOPENIA; LIFE EXPECTANCY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT ASSESSMENT; PATIENT CARE; PATIENT SAFETY; PHYSICAL EXAMINATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SEPSIS; STOMATITIS; UNITED STATES; VOMITING; ADJUVANT CHEMOTHERAPY; AGED; COLORECTAL TUMOR;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS;

EID: 33750606711     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. National Cancer Institute: SEER cancer statistics review, 1975-2001. Available at http://seer.cancer.gov/csr/1975_2001/results_merged/topic_med_age. pdf. Accessed May 4, 2006.
2. Extermann M, Balducci L, Lyman GH: What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 18:1709-1717, 2000.
3. Lichtman SM: Management of advanced colorectal cancer in older patients. Oncology (Williston Park) 19:597-602, 2005.
4. Extermann M: Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181-200, 2000.
5. Lichtman SM: Physiological aspects of aging. Implications for the treatment of cancer. Drugs Aging 7:212-225, 1995.
6. Talarico L, Chen G, Pazdur R: Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol 22:4626-4631, 2004.
7. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999.
8. Sawhney R, Sehl M, Naeim A: Physiologic aspects of aging: Impact on cancer management and decision making, Part I. Cancer J 11:449-460, 2005.
9. Newton JL: Changes in upper gastrointestinal physiology with age. Mech Ageing Dev 125:867-870, 2004.
10. Guslandi M, Pellegrini A, Sorghi M: Gastric mucosal defences in the elderly. Gerontology 45:206-208, 1999.
11. Kaplan C, Pasternack B, Shah H, et al: Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol 80:227-234, 1975.
12. Adachi T, Kawamura M, Owada M, et al: Effect of age on renal functional and orthostatic vascular response in healthy men. Clin Exp Pharmacol Physiol 28:877-880, 2001.
13. Swedko PJ, Clark HD, Paramsothy K, et al: Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 163:356-360, 2003.
14. Launay-Vacher V, Izzedine H, Rey JB, et al: Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 10:CR209-212, 2004.
15. Sokoll LJ, Russell RM, Sadowski JA, et al: Establishment of creatinine clearance reference values for older women. Clin Chem 40:2276-2281, 1994.
16. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976.
17. Marx GM, Blake GM, Galani E, et al: Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15:291-295, 2004.
18. Aapro M, Launay-Vacher V, Lichtman S, et al: A report from a SIOG Task Force on Renal Safety in the Elderly. International Society of Geriatric Oncology Newsletter. 1(1):1, 2005. Available at www.cancerworld.org/ cancerworldadmin/getStaticModFileaspx?id=893. Accessed May 4, 2006.
19. Trimble EL, Carter CL, Cain D, et al: Representation of older patients in cancer treatment trials. Cancer 74:2208-2214, 1994.
20. Kemeny MM, Peterson BL, Kornblith AB, et al: Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21:2268-2275, 2003.
21. Sateren WB, Trimble EL, Abrams J, et al: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109-2117, 2002.
22. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004.
23. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004.
24. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447-1456, 1989.
25. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990.
26. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990.
27. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001.
28. Schrag D, Gelfand SE, Bach PB, et al: Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results - Medicare. J Clin Oncol 19:3712-3718, 2001.
29. Sundararajan V, Grann VR, Jacobson JS, et al: Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population-based study. Cancer J 7:213-218, 2001.
30. Mahoney T, Kuo YH, Topilow A, et al: Stage III colon cancers: Why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 135:182-185, 2000.
31. Potosky AL, Harlan LC, Kaplan RS, et al: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192-1202, 2002.
32. Haller DG, Catalano PJ, Macdonald JS, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005.
33. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001.
34. Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 294:2703-2711, 2005.
35. Folprecht G, Cunningham D, Ross P, et al: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 15:1330-1338, 2004.
36. Iversen LH, Pedersen L, Riis A, et al: Age and colorectal cancer with focus on the elderly: Trends in relative survival and initial treatment from a Danish population-based study. Dis Colon Rectum 48:1755-1763, 2005.
37. Tsalic M, Bar-Sela G, Beny A, et al: Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): A prospective study in colorectal cancer patients. Am J Clin Oncol 26:103-106, 2003.
38. Patel K, Anthoney DA, Crellin AM, et al: Weekly 5-fluorouracil and leucovorin: Achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 15:568-573, 2004.
39. Scheithauer W, McKendrick J, Begbie S, et al: Oral capecitabine as an alternative to I.V. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 14:1735-1743, 2003.
40. Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704, 2005.
41. Diaz-Rubio E, Burris H, Douillard JY et al: Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts) (abstract 3737). J Clin Oncol 22(14S):258s, 2004.
42. Sargent D, Goldberg RM, Bleiberg H, et al: A pooled analysis to assess safety and efficacy of the FOLFOX4 regimen (bimonthlyoxaliplatin plus fluorouracil/leucovorin) in elderly patients with colorectal cancer. Proceedings of the World Congress of Gastrointestinal Cancer, Barcelona, page O-007, 2005.
43. Toumigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go gashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24:394-400, 2006.
44. Popescu RA, Norman A, Ross PJ, et al: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412-2418, 1999.
45. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004.
46. Rothenberg ML, Cox JV, DeVore RF, et al: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85:786-795, 1999.
47. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000.
48. Souglakos J, Pallis A, Kakolyris S, et al: Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology 69:384-390, 2005.
49. Sastre J, Marcuello E, Masutti B, et al: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 23:3545-3551, 2005.
50. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000.
51. Venook AP, Enders Klein C, Fleming G, et al: A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 14:1783-1790, 2003.
52. Cassidy J, Tabernero J, Twelves C, et al: XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084-2091, 2004.
53. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000.
54. Andre T, Bensmaine MA, Louvet C, et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560-3568, 1999.
55. Mattioli R, Massacesi C, Recchia F, et al: High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 16:1147-1151, 2005.
56. Comella P, Natale D, Farris A, et al: Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group trial 0108. Cancer 104:282-289, 2005.
57. Twelves CJ, Butts CA, Cassidy J, et al: Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: Post hoc analysis of a large phase II study. Clin Colorectal Cancer 5:101-107, 2005.
58. Comandone A, Pochettino P, Bergnolo P, et al: Capecitabine and oxaliplatin: A phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer (abstract 3681). J Clin Oncol 23(16S), 2005.
59. Lopez-Gomez L, Escudero P, Yubero A, et al: XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC) (abstract 3688). J Clin Oncol 22(14S), 2004.
60. Oh D-Y, Kim Y-J, Han S-W, et al: Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC) (abstract 3720). J Clin Oncol 23(16S), 2005.
61. Feliu J, Escudero P, Llosa F, et al: Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: An Oncopaz Cooperative Group study. J Clin Oncol 23:3104-3111, 2005.
62. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
63. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract 2). J Clin Oncol 23(16S):1s, 2005.
64. Hochster HS, Welles L, Hart L, et al: Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): Tree 1 & 2 studies (abstract 3515). J Clin Oncol 23(16S), 2005.
65. Mass RD, Fyfe G, Hambleton J, et al: Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis (abstract 3616). J Clin Oncol 22(14S), 2004.
66. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005.
67. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004.
68. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004.
69. Cunningham D, Humblet Y, Siena S, et al: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) (abstract 1012). Proc Am Soc Clin Oncol 22:252, 2003.
70. Tabernero JM, Van Cutsem E, Sastre J, et al: An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results (abstract 248). J Clin Oncol 22(14S), 2004.
71. Extermann M, Aapro M, Bernabei R, et al: Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the Task Force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241-252, 2005.
72. Hurria A, Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 104:1998-2005, 2005.